Evidence map›Paper›PMID 27002756›Full record

ArticleCancer biomarkers : section A of Disease markers2016

Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.

Piotr Hogendorf, Adam Durczyński, Aleksander Skulimowski, Anna Kumor, Grażyna Poznańska, Janusz Strzelczyk

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Challenges of early detection of pancreatic cancer.The Journal of clinical investigation · 2025
    Review
  3. Proteomics in pancreatic cancer.Biomarker research · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. The Immune Microenvironment in Pancreatic Cancer.International journal of molecular sciences · 2020
    Review
  12. Lipocalin-2 expression and function in pancreatic diseases.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2020
    Review
  13. Review
  14. Review
  15. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer.Canadian journal of gastroenterology & hepatology · 2018
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Piotr HogendorfDepartment of General and Transplant Surgery, Medical University of Lodz, Lodz, Poland.
Adam DurczyńskiDepartment of General and Transplant Surgery, Medical University of Lodz, Lodz, Poland.
Aleksander SkulimowskiDepartment of General and Transplant Surgery, Medical University of Lodz, Lodz, Poland.
Anna KumorDepartment of Pulmonology and Allergy, Medical University of Lodz, Lodz, Poland.
Grażyna PoznańskaDepartment of Anesthesiology and Intensive Care, Medical University of Lodz, Lodz, Poland.
Janusz StrzelczykDepartment of General and Transplant Surgery, Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently pancreatic cancer is the fourth leading cause of cancer-related death worldwide. Because of its late manifestation and consequent dismal prognosis, there is an urgent need to develop highly sensitive and specific marker. Neutrophil Gelatinase-Associated Lipocalin (NGAL) recently emerged as a protein playing an important role in carcinogenesis of various neoplasms.

objectiveOur aim was to assess the potential of urine and bile concentration of NGAL in differentiating pancreatic adenocarcinoma from chronic pancreatitis.

methodsForty-two patients operated on due to pancreatobiliary lesions were enrolled in this study. All enrolled patients had eGFR within reference range. Levels of CEA, CA 125 and Ca19-9 were assessed using standard laboratory protocols. A sample of urine was collected prior to the surgery. Intraoperatively a 5 ml sample of bile was collected directly from the common bile duct. Bile and urine levels of NGAL were measured using a ELISA kit. After standard pathological examination of specimens obtained during surgery, patients were divided into 2 groups: 21 patients with pancreatic adenocarcinoma and 15 patients with focal chronic pancreatitis.

resultsNGAL concentration in bile in patients with PDAC vs CP was 75.72 ± 16.05 ng/mL vs 62.62 ± 18.6 ng/mL respectively (p= 0,011). NGAL concentration in urine was 43.26 ± 21.21 ng/mL vs 17.96 ± 14.58 ng/mL (p= 0.002) respectively. In order to compare these markers with routinely used ones, ROC curve was built for Ca125 to establish cutoff point and in case of CA19-9 clinically used cutoff (≥ 37U/mL) was applied. Sensitivity and specificity for NGALurine with cutoff value of 27 ng/mL was 80.95% and 80% respectively, while these values for NGALbile were 71.43% and 80% respectively. Ca19-9 measured in plasma with clinically used cutoff value had sensitivity of 71.43% and specificity of 73.33%. Sensitivity and specificity for Ca 125 measured in plasma with cutoff value of 13 U/mL were 85.71% and 66.67% respectively.

conclusionsIn conclusion, NGAL in urine and bile are remarkably accurate in differentiating pancreatic mass due to chronic pancreatitis from pancreatic adenocarcinoma. Therefore, NGAL concentrations in bile and urine should be further investigated in order to assess their usefulness in early pancreatic adenocarcinoma diagnosis.

Indexed as

Biomarkers, TumorAgedBileCA-125 AntigenCA-19-9 AntigenDiagnosis, DifferentialFemaleHumansLipocalin-2MaleMiddle AgedPancreatic NeoplasmsPancreatitis, ChronicROC CurveSensitivity and SpecificityBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenLipocalin-2cancer biomarkerfocal chronic pancreatitisNeutrophil Gelatinase Associated Lipocalinpancreatic adenocarcinomaPancreatic cancer

Identifiers

PMID27002756
PMCPMC13016520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.